Biocon Q1 Review - Biosimilars Recover; Generics Slip: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Biocon Ltd. reported revenue in line with estimates but profitability was lower than expected for the Q1 FY22 results.
Biosimilar segment recovered supported by Covid-19 related drugs however, generics impacted due to lockdown.
Consolidated revenues grew 3.9% year-on-year to Rs 17.6 billion (our estimate: Rs 17.4 billion), adjusted Ebitda margin dropped 230 basis points YoY (down 160 basis points QoQ) to 22.1% (our estimate: 25.0%) and adjusted profit after tax declined 43.5% YoY to Rs 844 million (our estimate: Rs 1.5 billion).
Lower gross margin and higher expenses kept Biocon's margins in check.
However, new launches coupled with recovery in the environment would support margins in the near term.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.